Study of CALR gene changes in blood cancers
Treatments studied
Part of Blood & lymphatic, Heart & circulation clinical trials.
This study looks at cells from people with a specific gene change called CALR, found in some blood cancers (myeloproliferative neoplasms). It aims to better understand how the disease works. No new treatments are being tested, but you may help researchers learn more about your condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a type of blood cancer called myeloproliferative neoplasm (MPN)
- You have a specific gene change known as a CALR mutation
- You do not have a JAK2 V617F mutation (a different gene change)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how much of a specific gene change (CALR) you have, and whether it helps doctors diagnose and follow people with certain blood cancers over time. It mainly involves using samples and medical data rather than testing a new drug.
This study looks at how a type of white blood cell (monocyte) affects myeloproliferative neoplasms, a group of blood cancers. It aims to help doctors better understand these diseases and improve treatment.
This study looks at what leads to specific blood cancers and related blood disorders. If you have one of the listed conditions (or are being evaluated for it), you may be asked to join research that helps doctors understand why these illnesses happen.
This study tests an experimental drug called JNJ-88549968 in people with certain blood cancers (essential thrombocythemia or myelofibrosis) that have a CALR gene mutation. It may offer a new treatment option for those who haven't responded well to other therapies.
This trial tests a new drug, INCA035784, for people with myeloproliferative neoplasms (MPNs), a group of blood cancers. It may help if your MPN is called myelofibrosis (MF) or essential thrombocythemia (ET) and has a specific genetic change (CALR mutation), and you've already tried other treatments.
This trial tests a new drug, INCA033989, alone or with ruxolitinib for people with certain blood cancers called myeloproliferative neoplasms (MPNs). It may help those with a specific genetic change (CALR mutation) who have not had success with other treatments.
Hear when a new Myeloproliferative Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.